Eli Lilly announced a partnership with Nvidia to build what the companies describe as the most powerful supercomputer operated by a pharmaceutical company, intended to train large AI models for drug discovery and design. Lilly said the infrastructure will accelerate molecular modeling, generative chemistry and biological simulation workflows. Nvidia framed the deal as part of a broader push to lead biomedical AI computing; Lilly emphasized the capability to shorten discovery timelines by enabling larger models and richer datasets. The partners signaled plans to deploy the system across internal R&D programs and to use it for large‑scale molecular design and target prediction. The announcement intensifies competition for AI infrastructure in drug development and signals increased capital allocation to compute as a strategic R&D asset, with implications for biotech partnerships, talent allocation and model‑driven candidate generation.